India's API Firms Buoyant But Big Generic Cos See US-Led Swings
Repatriation Of APIs Likely?
Executive Summary
Leading Indian API firms are on a firm earnings footing and the evolving dynamics amid COVID-19 augur well for the segment, a new study by an Indian firm indicates, but notes that large cap generic firms in the country have seen sharp revenue growth swings over the decade.
You may also be interested in...
Why India Pharma Failed To Impress In 2020-22 Bull Run
Most Indian pharma stocks, including large firms, yielded double digit negative returns over the last 12 months while the overall market (Bombay Stock Exchange Sensex) delivered positive returns, a new study by an investment banking and consulting services firm indicates. The prognosis for fiscal years 2023/24, though, is optimistic.
Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Webinar Recording: India Supply Chain Issues Against The Backdrop Of COVID-19
Join Anju Ghangurde and Vibha Ravi in this recorded session from Informa Pharma Intelligence's recent 24-hour webinar series on COVID-19: Lessons Learned And A Path Forward.